Monod Bio
PrivateLast Round
Grant
Oct 15, 2025
Total Funding Raised
$27.25M
Company Overview
Monod Bio operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Grant round in October 2025.
Monod Bio is a biotechnology company that develops AI-powered de novo protein binders and biosensors for research and diagnostic applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Sensors, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Monod Bio Comparables
Compare Monod Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tierra Biosciences | 70% | |
| A-Alpha Bio | 64% | |
| Gator Bio | 63% |
For institutional investors. Book with your work email.
Monod Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 15, 2025 | ||||
| Grant | Sep 3, 2025 | ||||
| Seed | Aug 15, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Monod Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boom Capital Ventures | Seed |
| Boom Capital | Seed |
| Gates Family Foundation | Grant |
| Gates Foundation | Grant |
| Pack Ventures | Seed |
| Bill & Melinda Gates Foundation | Grant |
| Washington Research Foundation Capital | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 26, 2026
Robert J. Bujarski appointed to the Board of Directors.
- Dec 3, 2025
Integrated with Gator Bio for next-generation biosensing capabilities.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 8, 2026
On Oct 8th '26, Monod Bio, Inc. licenses its LuxSit Pro luciferase and NovoBody binding proteins non-exclusively to BPS Bioscience, Inc. in Washington and California for integration into future research products and services.
- integrates_withAug 26, 2026
On Aug 26th '26, Monod Bio, Inc. licenses its AI-designed LuxSit luciferase and NovoBodies to SignalChem Biotech Inc., which may incorporate them into custom luminescent assay development and protein-fusion services for research use in Washington and Canada.
For institutional investors. Book with your work email.
Monod Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Monod Bio's valuation, stock price, and market status.
Is Monod Bio a public or private company?
Monod Bio is a private company.
What is the current stock price of Monod Bio?
Monod Bio is a private company, so its shares have no public market price. Caplight tracks Monod Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Monod Bio worth (valuation)?
Valuation information for Monod Bio is not publicly available.
Can I buy Monod Bio stock?
Monod Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Monod Bio's last funding round?
Monod Bio's most recent funding round was Grant on October 15, 2025.
Who are the main investors in Monod Bio?
Key investors in Monod Bio include Boom Capital Ventures, Boom Capital, Gates Family Foundation, Gates Foundation, Pack Ventures.
Will Monod Bio IPO soon?
No public IPO plans have been announced for Monod Bio.
How can I track Monod Bio secondary market activity?
Caplight tracks bids, offers, and trades in Monod Bio's shares on secondary markets.